SEC Tracker
Get the app

Spyre Therapeutics SYRE

Spyre Therapeutics reports Q3 2026 financial results

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Raised over $400 million in gross proceeds in October 2026
  2. Reported $1.5 billion in pro forma cash as of September 30, 2026
  3. SKYLINE Part B trial is enrolling ahead of schedule
  4. SPY072 did not meet primary endpoints in PsA or axSpA sub-studies

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Spyre Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Schrodinger SDGR public float $1.1B, Jun 30, 2025
  2. Mannkind MNKD public float $1.1B, Jun 30, 2025
  3. Novavax NVAX public float $1.0B, Jun 30, 2025
  4. Harrow HROW public float $1.0B, Jun 30, 2025
  5. Aurinia Pharmaceuticals AUPH public float $1.0B, Jun 30, 2025